Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04, reports.
Brainstorm Cell Therapeutics Price Performance
Shares of BCLI opened at $0.88 on Wednesday. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.69. The business’s fifty day moving average price is $0.91 and its 200 day moving average price is $0.86. The stock has a market capitalization of $13.05 million, a PE ratio of -0.26 and a beta of 0.35.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics is a biotechnology company focused on developing cell therapies for neurodegenerative diseases. Its lead program, NurOwn, is an investigational treatment designed to use a patient’s own bone marrow-derived mesenchymal stem cells, modified to produce neurotrophic factors that may support nerve cells. The company has primarily studied NurOwn for amyotrophic lateral sclerosis (ALS). The therapy has been evaluated in clinical trials, including a Phase 3 study; it is investigational and has not been established as an approved treatment.
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
